Clinical Trials Logo

Recurrent Nasopharynx Carcinoma clinical trials

View clinical trials related to Recurrent Nasopharynx Carcinoma.

Filter by:
  • None
  • Page 1

NCT ID: NCT02706691 Not yet recruiting - Clinical trials for Head and Neck Squamous Cell Carcinoma

Pan FGFR Kinase Inhibitor BGJ398 in Treating Patients With FGFR1-3 Translocated, Mutated, or Amplified Recurrent Head and Neck Cancer

Start date: March 2018
Phase: Phase 2
Study type: Interventional

This phase IIa trial studies how well pan fibroblast growth factor receptor (FGFR) kinase inhibitor BGJ398 works in treating patients with FGFR1-3 translocated, mutated, or amplified head and neck cancer that has returned after a period of improvement. Pan FGFR kinase inhibitor BGJ398 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

NCT ID: NCT02538510 Active, not recruiting - Clinical trials for Head and Neck Squamous Cell Carcinoma

Pembrolizumab and Vorinostat in Treating Patients With Recurrent Squamous Cell Head and Neck Cancer or Salivary Gland Cancer That Is Metastatic and/or Cannot Be Removed by Surgery

Start date: October 8, 2015
Phase: Phase 1/Phase 2
Study type: Interventional

This phase I/II trial studies the side effects of pembrolizumab and vorinostat in treating patients with squamous cell head and neck cancer or salivary gland cancer that has come back, has spread to other places in the body and/or cannot be removed by surgery. Monoclonal antibodies, such as pembrolizumab, may interfere with the ability of tumor cells to grow and spread. Vorinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving pembrolizumab together with vorinostat may be a better treatment for head and neck cancer or salivary gland cancer.

NCT ID: NCT02339558 Active, not recruiting - Clinical trials for Recurrent Nasopharynx Carcinoma

Nivolumab in Treating Patients With Recurrent and/or Metastatic Nasopharyngeal Cancer

Start date: July 21, 2015
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well nivolumab works in treating patients with nasopharyngeal cancer that has returned after a period of improvement (recurrent) and/or has spread to other parts of the body (metastatic). Monoclonal antibodies, such as nivolumab, may block tumor growth in different ways by targeting certain cells.

NCT ID: NCT02137096 Completed - Clinical trials for Recurrent Nasopharynx Carcinoma

Autologous Stem Cell Transplantation for Patients With Recurrent Nasopharyngeal Carcinoma

Start date: June 2014
Phase: N/A
Study type: Observational

This is a pilot study to evaluate the response rates for patients undergoing high dose conditioning chemotherapy using Etoposide, Carboplatin and Ifosfamide followed by autologous stem cell transplantation for the treatment of recurrent Nasopharyngeal Cancer (NPC) in children, adolescents, and young adults.